McNeil Chooses Litigation To Challenge Glaxo’s OTC Flonase Ad Claims
This article was originally published in The Tan Sheet
Executive Summary
The J&J consumer products subsidiary, which markets the Zyrtec and Benadryl OTC allergy lines, foregoes industry self-regulation channels to hasten a decision in its challenge of Glaxo’s recently launched Flonase Allergy Relief.
You may also be interested in...
Flonase Allergy Relief Exclusivity Sliced Up By Label Carve-Out
FDA grants Glaxo market exclusivity for OTC as the first OTC fluticasone product, but with a label carve-out that limits exclusivity to the indication of “OTC use for temporary relief of ocular symptoms due to hay fever or other upper respiratory allergies.”
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.